Ferring Favorite To Get First Approval For Microbiota-Based Therapy
If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.
You may also be interested in...
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.
The Swiss specialty drug company gains a Phase III microbiome product for the prevention of recurrent Clostridium difficile infection and a broader platform for Microbiota Restoration Therapy.